The Company announced the appointment of new members to its Board of Directors to help guide its next phase of growth and innovation, including ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

US endocrinologists are favoring antithyroid drugs over radioactive iodine in initial Graves’ disease treatment, and new ...

AN orange zombie fungus that sprouts from the backs of caterpillars could be used to fight cancer, new research suggests. Scientists have found the fungus, called Cordyceps, works by stopping cell ...

Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

The drug can cause side effects such as reducing platelets ... argenx, Catalyst, Entrada Therapeutics, Genentech, and ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

3:47 PM ESTTechnology FDA approves Genentech drug aimed at subset of breast cancer patients FDA approves Genentech drug aimed at subset of breast cancer patients ...

Request a sample and discover the recent advances in T-cell malignancy treatment drugs @ T-cell Malignancies Pipeline Report ...

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.